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Summary Two human primary liver cancer cell-lines, PLC/PRF/5 and Hep3B, grown both in vitro and as
xenografts in nude mice were used to evaluate the chemotherapeutic potential of a new quinazoline antifolate
CB3717. Xenograft growth rate was followed both by serial serum alphafoetoprotein (AFP) measurement and
direct volume estimation. A dose regime of 200mg CB3717kg-1 body wtday-1 for 5 days caused a
significant reduction in growth rate, as measured by relative serum AFP, of both xenografts; PLC/PRF/5
derived xenograft growth was also inhibited by 125mg CB 3717kg-1 day-l for 5 days. Cell culture
experiments showed that the ID50 for the cell lines fell within the range of serum CB3717 concentration
achieved by a dose of 300mgm 2 given to patients. Treatment with CB3717 stimulated the incorporation of
exogenous thymidine into DNA by the tumour cells, presumably because of inhibition of the de novo pathway
and reduction of endogenous thymidine triphosphate pools. These results suggest that CB3717 may be a
useful new therapeutic agent in human primary liver cell carcinoma and that blocking the salvage pathway
may further increase efficacy.
Although primary hepatocellular carcinoma (PHC)
is uncommon in Northern Europe and North
America, its world wide incidence is estimated at
about 250,000 new cases annually (Waterhouse et
al., 1976). The prognosis of untreated patients with
PHC is dismal, the mean survival time from onset
of symptoms to death being only a few months
(Nagusue et al., 1984). Even the most effective
chemotherapy only increases the median survival
time by eleven weeks (Falkson et al., 1984). PHC is
thus one of the most common lethal tumours for
which there is an urgent need to find better
treatment.
For successful chemotherapy an exploitable
biochemical difference must exist between the host
cells and tumour cells. Thymidylate synthase is a
key target enzyme in cancer chemotherapy
(Danenberg, 1977); it catalyses the terminal step in
the de novo synthesis of deoxythymidylic acid
(dTMP) and is therefore a pivotal enzyme in DNA
synthesis. It cannot be circumvented by other
pathways except by thymidine kinase, a salvage
pathway enzyme, which converts pre-formed
thymidine into dTMP. Blockade of thymidylate
synthase therefore has a drastic effect on tissues
that require a high rate of DNA synthesis. Anti-
metabolites which inhibit thymidylate synthase,
either directly (e.g. 5 fluorouracil), or indirectly by
blocking dihydrofolate reductase (for example
methotrexate) have been used in cancer chemo-
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therapy for many years (Heidelberger et al., 1957;
Delmonte & Jukes, 1962). Problems of toxicity and
resistance have however arisen with these drugs.
Five fluorouracil may exert toxic effects on normal
cells due to its incorporation into RNA and target
cells may become resistant to its action by
overproducing deoxyuridilic acid (dUMP) or by
reducing the appropriate activating enzymes
(Chabner, 1982a). Methotrexate, on the other hand,
causes toxicity by inhibition of de novo purine
biosynthesis (Hryniuk, 1975; Chabner, 1982b) and
target cells may become resistant by virtue of
increased production of dihydrofolate reductase and
impaired methotrexate transport into the cell
(Niethammer & Jackson, 1975).
A new potent inhibitor of thymidylate synthase is
the quinazoline antifolate CB3717 (Figure 1) which
competes with N5, N10-methylene tetrahydrofolate
in the presence of dUMP (Jones et al., 1981;
Connick et al., 1983) (Figure 2). It has affinity for
the catalytic site on the enzyme by virtue of the
propargyl substitution at the N1O position. CB3717
requires no metabolic activation so resistance
cannot develop by lack of activating enzymes. Also
as its primary site of action is thymidylate synthase
rather than dihydrofolate reductase (Jackson et al.,
1983) it is less toxic than methotrexate as it does
not affect purine synthesis. Cell lines resistant to
methotrexate by virtue of raised dihydrofolate
reductase show little or no cross resistance to
CB3717 (Jones et al., 1981; Diddens et al., 1983).
Thymidylate synthase is increased in proliferating
cells, with a high rate of DNA synthesis including
PHC cells (Weber, 1983). Therefore inhibitors of
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Figure 1 Structure of CB3717 (N-(4-(N-((2-amino-4-hydroxyl-6-quinazolinyl)methyl)prop-2-ynylamino)
benozyl)-L-glutamic acid).
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Figure 2 Possible mode ofaction ofthe quinazoline inhibitor of thymidylate synthase, CB3717.
this enzyme could well be effective in the treatment
of human liver cancer. Indeed there are isolated
reports of significant palliation of this tumour by
hepatic artery infusion of both 5-fluorouracil
(Provan et al., 1968) and methotrexate (Gorgun &
Watne, 1967).
This paper describes the effect of CB3717 on two
PHC cell lines; PLC/PRF/5 (Alexander et al., 1976)
and a clonal derivative of Hep 3B (Aden et al.,
1979). This has been studied both in vitro and in
xenografts in nude mice (Bassendine et al., 1980).
Both cell lines produce the tumour marker alpha-
foetoprotein (AFP) and in the xenograft model
serum AFP concentrations correlate with tumour
mass (Bassendine et al., 1983). It is therefore
possible to follow growth of the xenograft PHCs by
serial serum AFP measurements as well as direct
tumour volume estimations.
Materials and methods
Cell-culture
PLC/PRF/5 cells were routinely grown in
MEM +10% foetal calf serum (FCS) and the clonal
derivative of Hep3B cells in HamsFIO+10% FCS
at 370C in humidified 95% air -5% CO2.
CB3717 studies For the purpose of determining
susceptibility to CB3717 Hep 3B cells were grown
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in MEM+10% FCS as Hams FIO medium
contains 4pM thymidine and this component may
reduce CB3717 toxicity. Cells were dispersed at a
density of 1 x 105 cells per tissue culture dish in
5ml MEM+10% FCS. After 24h the medium was
replaced with 5ml fresh medium (control) or 5ml
medium containing CB3717 at the following
concentrations: 300nM, 1MM, 3MM, 10pM or
30yM. After 72h the cells were removed with
trypsin and counted on a haemocytometer. Four
experiments were performed with each PHC cell
line with different batches of drug.
Thymidine and deoxyuridine: Incorporation
studies Blocking of thymidylate synthase should
cause a decrease in endogenous pool size of dTMP
and hence increased incorporation of exogenous
thymidine into DNA via the salvage pathway
(Figure 2). Inhibition of dTMP synthesis should
also decrease inrorporation into DNA of
derivatives of exogenous deoxyuridine. The effect of
CB3717 on thymidine and deoxyuridine
incorporation into DNA by the cells was therefore
investigated. Exponentially growing cell cultures
were incubated for 24h with MEM containing
300nM, 1MM, 3MM, 10MuM and 30pM CB3717 or
control medium. The cells were trypsinised,
counted, pelleted by centrifugation, washed twice
with PBS and resuspended in MEM without serum
to give a final cell concentration of 2 x 106 viable
cellsml- 50M1 of cell suspension, (1x 105 cells),
were dispensed into quadruplicate wells in a 96
multiwell plate (Titertek, Flow UK) containing
either 100nM (methyl[3H]) thymidine (sp. act.
45Cimmol-1) or 100nM deoxy (6-[3H] uridine
(sp.act. 15 Cimmol-1) (Amersham International,
UK), or MEM alone (control) or MEM containing
CB3717 to give a final CB3717 concentration of
300nM, 1MM, 3MM, 10pM or 30MM as
appropriate. Blanks were no thymidine, no
deoxyuridine or no cells. The plates were incubated
for 2h at 37°C with constant shaking to prevent
settling of the cells. The reaction was terminated by
washing the cells on to glass filters using a cell
harvester (Titertek), with distilled water (10sec)
followed by methanol (10sec). The filter was dried,
the disks punched into vials with 5ml scintillant
and counted on a LKB Rack B 1217. Incorporation
of [3H] thymidine and [3H] derivatives of
deoxyuridine per cell after treatment with CB3717
were expressed as % control values.
Animal experiments
Male nu/nu athymic mice (Chester Beatty Research
Institute, London) were sublethally irradiated
(450R) 24-48h prior to s.c. injection of either 1-
2 x 107 PLC/PRF/5 cells (Bassendine et al., 1980)
or 1-2 x 107 Hep 3B cells. Tumours appeared at the
site of innoculation 6-12 weeks later in 65% of the
mice given PLC/PRF/5 and 96% of the mice given
Hep 3B cells. Mice bearing visible growing tumours
- 5mm in diameter received either 125mg
CB3717/kg body wtday-' (low dose) or 200mg
CB3717kg-1 body wtday-1 (high dose) i.p. for 5
days (6 mice/group). CB3717 was dissolved in N/10
NaOH and the pH adjusted to 8.5 before i.p.
injection. In addition 6 mice bearing PLC/PRF/5
cell-derived xenograft received a second course of
200mg CB3717kg-1 body wtday i.p. for 5 days
(double dose) 9 days after the first one. Six control
mice received daily i.p. injections of saline adjusted
to pH 8.5.
Tumour growth was followed by direct tumour
volume measurement (Vernier callipers) every 7
days and serum collected from the mice at these
time points was assayed for AFP (Radioimmuno-
assay. Hoechst UK).
Results
Cell culture
CB3717 studies In both PHC cell lines significant
reduction in cell number, compared to controls
occurred with CB3717 concentrations of .1 MM.
The ID50 of drug (dose at which cell number is
50% of control) for PLC/PRF/5 is 1.48+0.55pM
(mean+s.d. of 4 experiments) and for Hep 3B is
1.95+ 1.57MM.
Thymidine and deoxyuridine incorporation
studies A dose-related increase in thymidine
incorporation and decrease in incorporation of
radioactivity from deoxyuridine occurred in both
PHC cell lines. The pooled results of 4 experiments
with each PHC cell line are shown in Figure 3. A
dose of 700nM CB3717 was sufficient to double
thymidine incorporation by Hep 3B cells and a
dose of 2.4MM CB3717 caused a 50% reduction in
radioactivity from deoxyuridine incorporation. In
PLC/PRF/5 cells thymidine uptake was doubled
with 4.8MM CB3717 and incorporation of radio-
activity from deoxyuridine halved with 26.uM
CB3717.
Animal experiments
Mice bearing PLC/PRF/5 derived xenografts
treated with high dose CB3717 showed a significant
reduction in tumour growth rate compared to
controls as measured both by relative serum AFP
(serum AFP concentration at time t/serum AFP364 N.J. CURTIN et al.
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Figure 3 Effect of increasing concentrations of
CB3717 on incorporation of [3H]-thymidine by
PLC/PRF/5 cells (v) and Hep 3B cells (0) in vitro;
[3H]-deoxyuridine by PLC/PRF/5 cells (C1) and Hep
3B cells (0) in vitro. Figure represents pooled data
from 4 experiments (bars represent s.e.m.). Significant
increase (P<0.05) of [3H] thymidine incorporation by
PLC/PRF/5 cells observed with 3 M, 1O UM and 30MM
CB3717 and by Hep 3B cells at all concentrations of
CB3717 used. Significant decrease (P<0.05) of
radioactivity from [3H] deoxyuridine incorporation by
PLC/PRF/5 observed with 30Mm CB3717 and by Hep
3B cells with 3pM, 10pM and 30pM CB3717.
*P<0.05.
concentration at time 0) and relative tumour
volume (estimate of tumour volume time t/volume
time 0). Double dose CB3717 caused a further
significant reduction in tumour growth rate
(Figures 4a,b). Low dose CB3717 treatment also
caused a significant reduction in relative serum
AFP; relative tumour volume was reduced but this
only achieved significance at 14 days after the start
of treatment (Figures 4a,b). During the low dose
study a small PLC/PRF/5 xenograft in one mouse
(serum AFP at start of treatment 900IUml-1)
regressed completely; the tumour was not palpable
for 6 weeks and serum AFP became undetectable.
However after 7 weeks the tumour was again
detected and serum AFP (Figure 5) and tumour
volume increased at a comparable rate to that of
controls. This animal was not included in the low
dose study group.
Hep 3B xenografts were less responsive to
CB3717 treatment, but a significant reduction in
relative serum AFP was seen with high dose
CB3717 (Figure 6a). The reduction found in
relative volume, compared to controls was not
significant for high dose or low dose CB3717
(Figure 6b).
A loss of body weight was observed in all the
mice during the week of CB3717 treatment but
subsequently some of this weight was regained.
Post-mortem examination of the treated mice
revealed some fibrous scarring of the kidneys; this
was more marked in those mice which received
double dose CB3717.
Discussion
This study shows that the growth of two human
hepatocellular carcinoma cell-lines can be inhibited
in vitro and in vivo by the quinazoline inhibitor of
thymidylate synthase, CB3717. The ID50 for both
cell lines is similar to that reported for other cell
lines (Jones et al., 1981; Diddens et al., 1983) and
falls within the range of plasma levels achieved
when CB3717 infusions have been administered to
patients in early clinical trials (Alison et al., 1985).
The thymidine incorporation experiments show that
the blocking of thymidylate synthase by increasing
concentrations of CB3717 causes a progressive
increase in the incorporation by exogenous
thymidine. This presumably reflects the reduction in
dTMP pool size and the activation of thymidine
kinase which converts the thymidine to dTMP for
DNA synthesis (Figure 2). Thymidine kinase
activity is known to be raised in liver cancer cells
(Weber, 1983; Curtin & Snell, 1983) so during
CB3717 treatment the availability of thymidine may
be a rate limiting factor in PHC growth. This is
supported by the observation that the growth
inhibitory effect of CB3717 on human lympho-
blastoid cells in vitro is prevented by 1OMM of
thymidine (Jackson et al., 1983) and the fact that
the cytotoxicity of the drug to L1210 cells is only
expressed when the thymidine concentration of
the medium is <0.1 M (Jackman et al., 1984). The
observed reduction in incorporation of radioactivity
from deoxyuridine by the PHC cells with increasing
concentrations of CB3717 presumably reflects the
inhibition of thymidylate synthase and consequent
expansion of endogenous dUMP pool. This
hypothesis is supported by experiments showing
that 16 h CB3717 treatment of lymphoblastoid
(W1-L2) cells in vitro with an ID50 concentration
of CB3717 causes an increase in cellular dUMP and
decrease in dTTP (Jackson et al., 1983).
We have studied the effect of CB3717 on these
two human PHCs in vivo by using an established
c(onn
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Figure 4 Effect of CB3717 treatment on growth of PLC/PRF/5 derived human liver cell cancer xenografts as
measured by (a) relative serum AFP (AFPt/AFPo) and (b) relative tumour volume (Vt/Vo) (0) saline
injected controls, (0, El) 125mg CB3717 i.p. for 5 days, (A) 200mg CB3717 i.p. for 5 days, (A) 200mg CB3717
i.p. for 5 days x 2). *P<0.05; **P<0.02; ***P<0.005.
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Figure 5 Effect of low dose CB3717 treatment
(125mg i.p. for 5 days) on growth of small PLC/PRF/5
derived xenograft as measured by serial serum alpha-
foetoprotein measurements. (Shaded area represents
normal range).
xenograft model (Bassendine et al., 1980), in which
serum AFP concentrations correlate with tumour
mass (Bassendine et al., 1983). In patients serial
serum AFP levels accurately reflect response to
chemotherapy (Johnson & Williams, 1980) and we
have used such measurements in the PHC xenograft
model to assess response to CB3717 treatment.
Reliable estimates of tumour volume are difficult to
obtain and cannot assess the proportion of necrotic
tissue within the tumour, whereas serum AFP is a
more sensitive reflection of viable tumour mass.
Serial serum AFP measurements of mice bearing
the PHC xenografts have shown that high dose
CB3717 inhibits the growth of both PLC/PRF/5
and Hep 3B derived xenografts. In addition low
dose CB3717 significantly retards the growth of
PLC/PRF/5 xenografts. This inhibition of PHC
growth by CB3717 may appear less dramatic than
the 'cures' obtained in 90% of animals bearing
L1210 derived murine tumour (Jones et al., 1981),
but it should be emphasised that these workers
started CB3717 treatment when the established
tumour was about 2 x 106 cells. By contrast we
have allowed the PHC xenografts to grow much
larger before starting chemotherapy in order to
mimic the situation existing in patients with
primary liver cell carcinoma, and have still
observed a significant growth inhibitory effect. It is
interesting to note that when the very small
PLC/PRF/5 derived xenograft was treated with low
dose CB3717, complete tumour regression was
observed.
The greater sensitivity of PLC/PRF/5 xenografts
to CB3717 may be due to a more rapid growth
rate. The PLC/PRF/5 xenograft doubling time is
-4.5 days (Figure 4), whereas the Hep 3B
xenograft doubling time is 6.5 days (Figure 6).
PLC/PRF/5 xenografts might therefore be expected
to have a greater requirement for DNA synthesis
and hence de novo TMP synthesis. Alternatively
the greater resistance of Hep 3B cells to CB3717
may be due to a greater activity of the salvage
pathway in the presence of CB3717. This is
supported by the greater increase in thymidine
incorporation observed in Hep 3B cells than
PLC/PRF/5 cells following CB3717 treatment. In
mice there is a high concentration of circulating
thymidine (Taylor et al., 1983) so a greater ability
of Hep 3B cells to activate thymidine kinase could
account for the greater resistance of Hep 3B
derived xenografts to CB3717. In vitro however the
thymidine concentration is much lower, so
thymidine kinase activation would not confer such
an advantage on Hep 3B cells, rendering the ID50
similar for both PHC cell lines. To test this
hypotheses fully thymidine kinase activity, dTTP
pool size and thymidine transport in cells needs to
be measured. If the salvage pathway is important
inhibitors of thymidine transport such as
dipyridamole may be of value (Nelson & Drake,
1984). Another possible reason for the greater
sensitivity of PLC/PRF/5 cells to CB3717 is that
thymidine may be rapidly broken down in these
cells by dihydrothymine dehydrogenase. This rate
limiting enzyme of thymidine catabolism has been
shown to be present in high levels in some rat
hepatoma cells (Jackson & Weber, 1976).
The fibrous scarring of the kidneys observed in
the mice bearing PHC xenografts is similar to other
studies in mice which indicate the dose limiting
toxicity is due to CB3717 precipitation in the
nephron (Newell et al., 1982). However these
preclinical toxicology studies have shown that this
can be prevented by alkalinization and clinically it
should be possible to avert potential renal toxicity
by appropriate scheduling.
The inhibition of growth of two human PLC cell
lines both in culture and xenograft models by
CB3717 suggests that this quinazoline antifolate
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Figure 6 Effect of CB3717 treatment on growth of Hep 3B derived human liver cell cancer xenografts as
measured by (a) relative serum AFP (AFPt/AFPo) and (b) relative tumour volume (Vt/Vo) (0) saline injected
controls, (0) 125mg CB3717 i.p. for 5 days, (A) 200mg CB3717 i.p. for 5 days. *P<0.05.
may be of potential benefit in the chemotherapy of
human PHC. A Phase II clinical study in human
primary liver cell carcinoma is currently in progress
in Newcastle.
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